IMMX vs. ANVS, RPHM, CELU, CALC, AEON, CKPT, ELDN, KZR, EGRX, and BLRX
Should you be buying Immix Biopharma stock or one of its competitors? The main competitors of Immix Biopharma include Annovis Bio (ANVS), Reneo Pharmaceuticals (RPHM), Celularity (CELU), CalciMedica (CALC), AEON Biopharma (AEON), Checkpoint Therapeutics (CKPT), Eledon Pharmaceuticals (ELDN), Kezar Life Sciences (KZR), Eagle Pharmaceuticals (EGRX), and BioLineRx (BLRX). These companies are all part of the "pharmaceutical preparations" industry.
Annovis Bio (NYSE:ANVS) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, community ranking, profitability, earnings and institutional ownership.
Annovis Bio currently has a consensus price target of $25.25, indicating a potential upside of 325.80%. Immix Biopharma has a consensus price target of $14.00, indicating a potential upside of 542.20%. Given Annovis Bio's stronger consensus rating and higher possible upside, analysts clearly believe Immix Biopharma is more favorable than Annovis Bio.
In the previous week, Annovis Bio and Annovis Bio both had 4 articles in the media. Annovis Bio's average media sentiment score of 0.97 beat Immix Biopharma's score of -0.25 indicating that Immix Biopharma is being referred to more favorably in the news media.
Annovis Bio's return on equity of -111.41% beat Immix Biopharma's return on equity.
Annovis Bio has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500.
Annovis Bio received 14 more outperform votes than Immix Biopharma when rated by MarketBeat users. However, 100.00% of users gave Immix Biopharma an outperform vote while only 94.74% of users gave Annovis Bio an outperform vote.
Immix Biopharma is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.
15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 38.3% of Annovis Bio shares are owned by insiders. Comparatively, 55.9% of Immix Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Immix Biopharma beats Annovis Bio on 9 of the 14 factors compared between the two stocks.
Get Immix Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immix Biopharma Competitors List
Related Companies and Tools
